Paradigm shift with menin inhibitor triplets: moving beyond older/unfit AML
Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the paradigm shift brought by menin inhibitor triplets, particularly the combination of azacitidine, venetoclax, and revumenib as frontline treatment for older or unfit patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). Dr Zeidner explains that the triplet has demonstrated high response rates, leading to the randomized Phase III EVOLVE-2 (NCT06652438), cAMeLot-2 (NCT06852222), and KOMET-017 (NCT07007312) trials. He also discusses efforts to extend menin inhibitor triplets to younger, fit patients, including the Phase II RAVEN study (NCT07605949) in KMT2A-rearranged AML. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
